2017 In Review: FDA's Cosmetics Slowdown Could Bolster Case For Legislative Jumpstart
This article was originally published in The Rose Sheet
Executive Summary
FDA's cosmetics activities fell off noticeably compared with 2016, and the change in the White House spurred the agency to begin looking for regulatory burdens to eliminate while shuffling priorities away from cosmetics to make do with proposed cuts in federal funding. In this climate, robust cosmetics oversight may depend on a legislative update, with multiple draft bills on the table.